American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Patients with Advanced Myelofibrosis Receiving Bomedemstat Exhibit Improved Clinical Outcomes Compared to JAK Inhibitors

ASH 2021 - Myelofibrosis

Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib. Read More ›

TGFβ-Regulated Progression of Thrombocytopenia Reduced in Patients with Advanced Myelofibrosis Receiving AVID200 Therapy

ASH 2021 - Myelofibrosis

TGFβ is a cytokine that enhances myelofibrosis disease progression. AVID200, a TGFβ1/3 inhibitor, may provide clinical benefit manifesting as improved platelet counts in patients with myelofibrosis who have thrombocytopenia. Read More ›

Tagraxofusp Monotherapy Demonstrated Clinical Efficacy in Patients with Advanced Myelofibrosis and Refractory to JAK Inhibitor Therapy

ASH 2021 - Myelofibrosis

JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data. Read More ›

Association Between IPSS Score and JAK Mutation Characterize Patients with Myelofibrosis at High Risk for Thrombosis

ASH 2021 - Myelofibrosis

Thrombus formation in patients with myelofibrosis is a common marker of disease progression. The relationship between IPSS score and JAK mutation status may distinguish patients at high risk for thrombosis, which may serve as a guide to therapy decisions. Read More ›

Analysis of Patients with Essential Thrombocythemia or Myelofibrosis Enrolled in Clinical Trials in Academic versus Community Centers

ASH 2021 - Myelofibrosis

Patients with essential thrombocythemia and myelofibrosis enroll in various studies in both academic and community centers across the United States. The comparison of patient characteristics across these centers may provide valuable insight into the management of these myeloproliferative neoplasms. Read More ›

Fludarabine-Busulfan Conditioning Demonstrates Improved Outcomes in Patients with Myelofibrosis After Allo-HSCT

ASH 2021 - Myelofibrosis

Conditioning regimens for allo-HSCT includes either myeloablative conditioning or reduced-intensity conditioning. The use of fludarabine/busulfan appears to deliver better patient outcomes after transplant compared with other commonly used conditioning regimens. Read More ›

Spleen Size Prior to Fedratinib Treatment May Impact Spleen Responses and Symptom Reduction in Myelofibrosis Patients

ASH 2021 - Myelofibrosis

Clinical trials have demonstrated JAK2 inhibition with fedratinib effectively reduces spleen volume and improves symptoms in patients with myelofibrosis. It has yet to be determined whether spleen size before fedratinib therapy influences these effects. Read More ›

Pacritinib Demonstrates Superior Efficacy to Low-Dose Ruxolitinib in Myelofibrosis Patients with Thrombocytopenia

ASH 2021 - Myelofibrosis

Low-dose ruxolitinib is an approved therapy for patients with myelofibrosis who have thrombocytopenia, but efficacy may be limited. Evidence from PERSIST-2 indicate pacritinib at full dose may provide additional clinical benefit with a similar safety profile compared with ruxolitinib. Read More ›

Enhanced Benefit of Extended Treatment with Pacritinib in Patients with Advanced Myelofibrosis and Cytopenias

ASH 2021 - Myelofibrosis

Pacritinib is currently under investigation in multiple trials and demonstrated efficacy and safety in patients with advanced myelofibrosis during the study period. Patients who continue pacritinib on a compassionate-use basis show further improvement in clinical outcomes. Read More ›

Navtemadlin Improves Clinical Outcomes in Patients with Relapsed/Refractory Myelofibrosis by Disease Modification

ASH 2021 - Myelofibrosis

Patients with myelofibrosis who are refractory to JAK inhibitors often lack effective treatment options that not only manage symptoms but can also reduce disease progression. Navtemadlin may improve disease burden in these patients through disease modification. Read More ›

American Society of Hematology (ASH)

Page 1 of 43